Novartis Healthcare Philippines, Inc.
- World Health Organization (WHO)
- Department of Health (WHO)
- Local Government Units (LGUs)
- Leprosy advocacy groups
- Novartis Foundation for Sustainable Development
Since 2000 Novartis, through the WHO, has provided at no cost close to 100 percent of the global supply of multidrug therapy (MDT) against leprosy. This donation, which is equivalent to US$77M, has helped cure approximately 5 million patients worldwide. Since 2000, Novartis has supplied at no cost more than 47,000 MDT courses to the Philippines, accounting for over 60 percent of WHO’s total MDT supply to the country since 1995. Recommended by WHO since 1981, MDT has revolutionized the treatment of leprosy. It consists of 3 drugs: dapsone, rifampicin and clofazimine. MDT has made it possible to cure patients, interrupt the transmission of leprosy and prevent disabilities. Even patients with the severest form of the disease show visible clinical improvement within weeks of starting treatment. Two of the three drugs used in MDT were developed in the research laboratories of Novartis. In October 2010, Novartis and WHO formally announced the extension of their anti-leprosy collaboration until 2015. Novartis will continue to provide free MDT medicines. The company’s donation to WHO, valued at about US$26M, will treat an estimated 1.1 million leprosy patients worldwide during the five-year commitment. In addition, Novartis will provide up to US$2.5M to cover costs incurred by WHO for handling the donation and logistics.
Saan maaaring pumunta?
Municipal or City Health Center
Saan tatawag para sa mga katanungan tungkol sa programa?
Patients can get in touch with their Municipal or City Health Center.